Evidence map›Paper›PMID 39010022›Full record

SynthesisWorld journal of surgical oncology2024

Efficacy and toxicity of KRAS

Shoutao Dang, Shuyang Zhang, Jingyang Zhao, Wei Li

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. UnlockingCurrent oncology (Toronto, Ont.) · 2026
    Review
  4. Review
  5. Annals of gastroenterology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shoutao DangCancer Center, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Town, Beijing, China.
Shuyang ZhangCancer Center, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Town, Beijing, China.
Jingyang ZhaoCancer Center, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Town, Beijing, China.
Wei LiCancer Center, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Town, Beijing, China. weili8989@ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy and toxicity of KRAS

methodsClinical trials evaluating KRAS

resultsTen studies with 925 heavily pretreated advanced patients harboring KRAS

conclusionsKRAS

Indexed as

MutationNeoplasmsProto-Oncogene Proteins p21(ras)Antineoplastic AgentsHumansPrognosisSurvival RateAntineoplastic AgentsKRAS protein, humanProto-Oncogene Proteins p21(ras)KRASG12C inhibitorsMeta-analysisSolid tumors

Identifiers

PMID39010022
PMCPMC11251097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.